William Blair & Company
KRTX

William Blair & Company’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

William Blair & Company’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,625
Closed -$499K – 1784
2019
Q4 		$499K Buy
+6,625
New +$290K ﹤0.01% 989

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

William Blair & Company's KRTX Position: Q1 2020 in Review

William Blair & Company sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2020, closing a stake of 6,625 shares — an estimated $499K sold.

William Blair & Company first reported a position in KRTX in Q4 2019 and held it in 1 quarter. The position peaked at $499K in Q4 2019. 99 funds tracked by Wall St. Rank hold KRTX as of Q1 2020.

  • William Blair & Company reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • William Blair & Company sold 6,625 Karuna Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $499K.
  • William Blair & Company first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • William Blair & Company's Karuna Therapeutics, Inc. Common Stock position peaked at $499K in Q4 2019.
  • 99 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2020.

Based on William Blair & Company's 13F filing for Q1 2020, filed 11 May 2020.